Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

NCT02847403 on ClinicalTrials.gov · last registry update 2021-08-17

A small phase 3 — 40 participants, against a typical 424. Completed July 2019.

Status: UNKNOWN
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Sponsor type: Other
Enrollment: 40
Started: 2016-02
Primary completion: 2019-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement of ADAS-cog Alzheimer's Disease Assessment Scale defined by ADAS-cog score at 16 (V2) and at 32 weeks (V3) compared to baseline

Conditions studied

Dysglycemia · Cognitive Deficit

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.